Literature DB >> 30827944

Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab.

Roberto Maglie1, Emiliano Antiga1, Lavinia Quintarelli1, Alice Verdelli1, Marzia Caproni1.   

Abstract

Entities:  

Year:  2019        PMID： 30827944     DOI： 10.1684/ejd.2019.3499

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  3 in total

1.  Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.

Authors:  Marina Alexandre; Gérôme Bohelay; Thomas Gille; Christelle Le Roux-Villet; Isaac Soued; Florence Morin; Frédéric Caux; Sabine Grootenboer-Mignot; Catherine Prost-Squarcioni
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

2.  Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Authors:  Peng Cao; Wenjing Xu; Litao Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

Review 3.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.